Download presentation
Presentation is loading. Please wait.
Published byShannon Bell Modified over 6 years ago
1
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence Mariya Rozenblit, BA, Mayte Suarez-Farinas, PhD, Avner Shemer, MD, Saakshi Khattri, MD, Patricia Gilleaudeau, NP, Mary Sullivan- Whalen, NP, Xiuzhong Zheng, MSc, Hui Xu, MSc, Irma Cardinale, MSc, James G. Krueger, MD, PhD, Emma Guttman-Yassky, MD, PhD Journal of Allergy and Clinical Immunology Volume 134, Issue 4, Pages (October 2014) DOI: /j.jaci Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Histologic changes corresponding with CsA RDGP. A, Representative images of AD lesions after CsA treatment. Representative staining in nonlesional (NL) and lesional (LS) skin before and after 2 and 12 weeks of CsA treatment, with black arrows indicating increased staining of CLDN8 (B) and LEP (C) and white arrows indicating faint/discontinuous staining of CLDN23 (D). E, Increase in langerin+ cells after CsA treatment. Scale bars = 100 μm. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig E1 Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.